Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.345
Buy
RSI(14)
65.741
Neutral
STOCH(KDJ)(9,3,3)
66.355
Sell
ATR(14)
1.522
High Vlolatility
CCI(14)
70.867
Neutral
Williams %R
21.003
Buy
TRIX(12,20)
1.618
Sell
StochRSI(14)
0.000
Sell
Search
Xencor Inc
XNCRAdd to Watchlist
20.210USD
-1.280-5.96%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.50BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-5.96%
5 Days
+3.96%
1 Month
+31.40%
6 Months
+67.16%
Year to Date
+32.01%
1 Year
+153.26%
Key Figures
21.500Open
21.570High
1.32MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.78%Turnover Ratio
21.490Prev. Close
19.770Low
19.88MTurnover
LossP/E Static
2.90P/B
0.00%Div Yield TTM
-21.01%ROA
18.69052wk High
1.12Volume Ratio
-232.62MNet Profit
74.06MShares
-2.2942EPS TTM
0.92Beta
-29.84%ROE
6.92052wk Low
8.38%Amplitude
100.00%Gross Margin
1.50BMarket Cap
11.35Reward/Risk
3.90%Risk Rate
TradingKey Stock Score of Xencor Inc
Currency: USD Updated: 2026-07-31Key Insights
Xencor Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 61 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 29.64.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance over the past month, the company shows weak fundamentals and technicals, which don't support the current strong trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Xencor Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Xencor Inc Highlights
StrengthsRisks
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Fairly Valued
The company’s latest PE is -8.81, at a medium 3-year percentile range.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 45.09K shares of this stock.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
29.636
Target Price
+51.75%
Upside Space
Xencor Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
14
analysts
Buy
Current Rating
29.636
Target Price
+51.75%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Xencor Inc
XNCR
14
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
20.212
Sell
MA10
19.880
Buy
MA20
17.755
Buy
MA50
14.764
Buy
MA100
13.506
Buy
MA200
13.807
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Xencor Inc Info
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Ticker SymbolXNCR
CompanyXencor Inc
CEODahiyat (Bassil I)
Websitehttps://xencor.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Xencor Inc (XNCR)?
The current price of Xencor Inc (XNCR) is 20.21.
What is the symbol of Xencor Inc?
The ticker symbol of Xencor Inc is XNCR.
What is the 52-week high of Xencor Inc?
The 52-week high of Xencor Inc is 18.69.
What is the 52-week low of Xencor Inc?
The 52-week low of Xencor Inc is 6.92.
What is the market capitalization of Xencor Inc?
The market capitalization of Xencor Inc is 1.50B.
Is Xencor Inc (XNCR) currently rated as Buy, Hold, or Sell?
According to analysts, Xencor Inc (XNCR) has an overall rating of Buy, with a price target of 29.64.
What is the Earnings Per Share (EPS TTM) of Xencor Inc (XNCR)?
The Earnings Per Share (EPS TTM) of Xencor Inc (XNCR) is -1.24.